Abstract
Huntington disease is a rare neurodegenerative movement disorder characterised by abrupt, irregular, and purposeless ‘dance-like’ movements. Huntington disease is a genetic condition inherited in an autosomal dominant fashion, with expansion of the trinucleotide CAG on the short arm of chromosome 4 identified as single genetic change. At a population level, age at onset of motor manifestations is inversely proportional to CAG repeat length, with higher numbers of repeats correlating with earlier development of symptoms. Higher CAG lengths (for instance, 55 and over) can lead to a juvenile form of Huntington disease (‘Westphal variant’), with more pronounced rigidity, akinesia, and cognitive changes, as well as psychiatric symptoms including depression, anxiety, impulsivity, and aggression. Overall, behavioural symptoms are common in Huntington disease. Specific changes in personality and behaviour are often more disabling than the motor features. Affective symptoms occur in about half of the patients and anxiety in about 20%. Irritability is also highly prevalent and usually occurs in the wider context of psychorigidity and deficits in social cognition. Dementia develops in all patients with Huntington disease later in the illness, whereas alterations in social cognition can occur in earlier stages of the illness.
The name ‘chorea’ is given to the disease on account of the dancing propensities of those who are affected by it, and it is a very appropriate designation
George Huntington, On chorea (1872)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Books
Bates G, Tabrizi S, Jones L, editors. Huntington’s disease. 4th ed. Oxford: Oxford University Press; 2014.
Naff CF. Huntington’s disease. New York: Greenhaven Press; 2012.
Nguyen HHP. In: Cenci MA, editor. Behavioral neurobiology of Huntington’s disease and Parkinson’s disease. New York: Springer; 2015.
Quarrell O. Huntington’s disease: the facts. 2nd ed. Oxford: Oxford University Press; 2008.
Articles
Anderson KE. Huntington’s disease. Handb Clin Neurol. 2011;100:15–24.
Baig SS, Strong M, Quarrell OW. The global prevalence of Huntington’s disease: a systematic review and discussion. Neurodegener Dis Manag. 2016;6:331–43.
Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.
Bora E, Velakoulis D, Walterfang M. Social cognition in Huntington’s disease: a meta-analysis. Behav Brain Res. 2016;297:131–40.
Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington’s disease. Lancet Neurol. 2015;14:1135–42.
Coppen EM, Roos RA. Current pharmacological approaches to reduce chorea in Huntington’s disease. Drugs. 2017;77:29–46.
Crozier S, Robertson N, Dale M. The psychological impact of predictive genetic testing for Huntington’s disease: a systematic review of the literature. J Genet Counsel. 2015;24:29–39.
Dale M, van Duijn E. Anxiety in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2015;27:262–71.
Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. Neurol Clin. 2015;33:101–14.
Eddy CM, Parkinson EG, Rickards EHG. Changes in mental state and behaviour in Huntington’s disease. Lancet Psychiatry. 2016;3:1079–86.
Fisher CA, Sewell K, Brown A, Churchyard A. Aggression in Huntington’s disease: a systematic review of rates of aggression and treatment methods. J Huntington’s Dis. 2014;3:319–32.
Genetic Modifiers of Huntington’s disease (GEM-HD) Consortium. Identification of genetic factors that modify clinical onset of Huntington’s disease. Cell. 2015;162:516–26.
Groves M, van Duijn E, Anderson K, Craufurd D, Edmondson MC, Goodman N, van Kammen D, Goodman L. An international survey-based algorithm for the pharmacological treatment of irritability in Huntington’s disease. PLoS Curr. 2011;3:RRN1259.
Hartmann CJ, Groiss SJ, Vesper J, Schnitzler A, Wojtecki L. Brain stimulation in Huntington’s disease. Neurodegener Dis Manag. 2016;6:223–36.
Huntington G. On chorea. Med Surg Rep. 1872;26:317–21.
Guidelines for the molecular genetics predictive test in Huntington’s disease. International Huntington Association (IHA) and World Federation of Neurology (WFN) Research Group on Huntington’s disease. Neurology. 1994;44:1533–66.
Mason SL, Barker RA. Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature. Expert Opin Pharmacother. 2016;17:41–52.
McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25:24–34.
Mestre TA, van Duijn E, Davis AM, Bachoud-Lévi AC, Busse M, Anderson KE, Ferreira JJ, Mahlknecht P, Tumas V, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P, Members of the MDS Committee on Rating Scales Development. Rating scales for behavioral symptoms in Huntington’s disease: critique and recommendations. Mov Disord. 2016;31:1466–78.
Mittal SK, Eddy C. The role of dopamine and glutamate modulation in Huntington disease. Behav Neurol. 2013;26:255–63.
Morreale MK. Huntington’s disease: looking beyond the movement disorder. Adv Psychosom Med. 2015;34:135–42.
Moulton CD, Hopkins CW, Bevan-Jones WR. Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease. Mov Disord. 2014;29:1556–61.
Nance MA. Genetic counseling and testing for Huntington’s disease: a historical review. Am J Med Genet Part B: Neuropsychiatric Genet. 2017;174:75–92.
Nopoulos PC. Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci. 2016;18:91–8.
Novak MJ, Tabrizi SJ. Huntington’s disease. Br Med J. 2010;340:c3109.
Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11:474–83.
Pidgeon C, Rickards H. The pathophysiology and pharmacological treatment of Huntington disease. Behav Neurol. 2013;26:245–53.
Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083–91.
Quigley J. Juvenile Huntington’s disease: diagnostic and treatment considerations for the psychiatrist. Curr Psychiatry Rep. 2017;19:9.
Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ, Smeeth L. The prevalence of Huntington’s disease. Neuroepidemiology. 2016;46:144–53.
Rosenblatt A. Neuropsychiatry of Huntington’s disease. Dialogues Clin Neurosci. 2007;9:191–7.
Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83–98.
Rüb U, Vonsattel JP, Heinsen H, Korf HW. The neuropathology of Huntington’s disease: classical findings, recent developments and correlation to functional neuroanatomy. Adv Anat Embryol Cell Biol. 2015;217:1–146.
Scheuing L, Chiu CT, Liao HM, Linares GR, Chuang DM. Preclinical and clinical investigations of mood stabilizers for Huntington’s disease: what have we learned? Int J Biol Sci. 2014;10:1024–38.
Shannon KM, Fraint A. Therapeutic advances in Huntington’s disease. Mov Disord. 2015;30:1539–46.
Sharma M, Deogaonkar M. Deep brain stimulation in Huntington’s disease: assessment of potential targets. J Clin Neurosci. 2015;22:812–7.
Sitek EJ, Thompson JC, Craufurd D, Snowden JS. Unawareness of deficits in Huntington’s disease. J Huntington’s Dis. 2014;3:125–35.
Tarolli CG, Chesire AM, Biglan KM. Palliative care in Huntington disease: personal reflections and a review of the literature. Tremor Other Hyperkinet Mov. 2017;7:454.
Teixeira AL, de Souza LC, Rocha NP, Furr-Stimming E, Lauterbach EC. Revisiting the neuropsychiatry of Huntington’s disease. Dement Neuropsychol. 2016;10:261–6.
The Huntington’s Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83.
Unti E, Mazzucchi S, Palermo G, Bonuccelli U, Ceravolo R. Antipsychotic drugs in Huntington’s disease. Expert Rev Neurother. 2017;17:227–37.
Vale TC, Cardoso F. Chorea: a journey through history. Tremor Other Hyperkinet Mov. 2015;5.
Van Duijn E, Craufurd D, Hubers AM, Giltay EJ, Bonelli R, Rickards H, Anderson KE, van Walsem MR, van der Mast RC, Orth M, Landwehrmeyer GB, the European Huntington’s Disease Network Behavioural Phenotype Working group. Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85:1411–8.
Wexler NS, Collett L, Wexler AR, Rawlins M, Tabrizi SJ, Douglas I, Smeeth L, Evans SJ. Incidence of adult Huntington’s disease in the UK: a UK-based primary care study and systematic review. Br Med J Open. 2016;6:e009070.
Wyant KJ, Ridder AJ, Dayalu P. Huntington’s disease: update on treatments. Curr Neurol Neurosci Rep. 2017;17:33.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Cavanna, A.E. (2018). Huntington Disease. In: Motion and Emotion. Springer, Cham. https://doi.org/10.1007/978-3-319-89330-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-89330-3_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-89329-7
Online ISBN: 978-3-319-89330-3
eBook Packages: MedicineMedicine (R0)